Nimodipine (Nimodipine) Patent Expiration, LOE Window & CMS Spending

Nimodipine (Nimodipine) by Bionpharma: Multi-Source Generic Molecule, 4 AB generics, $952K 2024 CMS Part D & Medicaid spend, and $2,133 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBionpharma
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$952K
2024 Medicare Part D Spend$797K
2024 Medicaid Spend$155K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,133 intro WAC)